v3.26.3
Reportable Segment Information - Summary of Financial Information for Each Reportable Segment (Details) - USD ($)
$ in Millions
12 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2024
Segment Reporting Information [Line Items]      
Sales $ 1,863 $ 1,824 $ 2,113
Cost of sales 1,262 1,275 1,495
Selling, general and administrative expense 377 344 404
Research and development expense 55 54 55
Equity and other income 4 4 6
Goodwill impairment and loss on divestitures, net 8 867 115
Operating income (loss) 105 (775) (26)
Net interest and other expense (income) 40 33 (24)
Other net periodic benefit (income) loss (4) 1 22
Income (loss) from continuing operations before income taxes 69 (809) (24)
EBITDA [1] 290 (538) 248
Depreciation expense [2] 125 174 198
Amortization expense 60 63 76
Additions to property, plant and equipment 88 98 137
Assets 4,527 4,611  
Property, plant and equipment, net 1,134 1,201  
Operating Segments [Member]      
Segment Reporting Information [Line Items]      
Selling, general and administrative expense 260 232 252
Research and development expense 51 52 52
Equity and other income 1 1 0
Goodwill impairment and loss on divestitures, net 0 706 0
Operating income (loss) 231 (502) 238
EBITDA [1] 415 (265) 512
Depreciation expense 124 174 198
Intersegment Eliminations [Member]      
Segment Reporting Information [Line Items]      
Sales [3] (39) (42) (47)
Cost of sales (39) (42) (47)
Life Sciences [Member]      
Segment Reporting Information [Line Items]      
Sales 671 641 810
Goodwill impairment and loss on divestitures, net 0 375 0
Amortization expense 18 18 23
Additions to property, plant and equipment 31 49 61
Assets 1,422 1,498  
Property, plant and equipment, net 440 481  
Life Sciences [Member] | Operating Segments [Member]      
Segment Reporting Information [Line Items]      
Sales 671 641 810
Cost of sales 411 418 515
Selling, general and administrative expense 97 77 89
Research and development expense 14 15 15
Equity and other income 0 0 0
Operating income (loss) [4] 131 (262) 168
EBITDA [1] 187 (187) 229
Depreciation expense [5] 38 57 38
Personal Care [Member]      
Segment Reporting Information [Line Items]      
Goodwill impairment and loss on divestitures, net 0 0 0
Amortization expense 32 35 43
Additions to property, plant and equipment 9 7 11
Assets 701 751  
Property, plant and equipment, net 106 101  
Personal Care [Member] | Operating Segments [Member]      
Segment Reporting Information [Line Items]      
Sales 592 577 634
Cost of sales 350 345 398
Selling, general and administrative expense 87 84 95
Research and development expense 23 25 26
Equity and other income 1 1 0
Operating income (loss) [6] 101 90 73
EBITDA [1] 161 155 152
Depreciation expense [7] 28 30 36
Specialty Additives [Member]      
Segment Reporting Information [Line Items]      
Sales 504 511 572
Goodwill impairment and loss on divestitures, net 0 331 0
Amortization expense 9 9 10
Additions to property, plant and equipment 42 34 61
Assets 964 1,020  
Property, plant and equipment, net 463 484  
Specialty Additives [Member] | Operating Segments [Member]      
Segment Reporting Information [Line Items]      
Sales 504 511 572
Cost of sales 423 433 522
Selling, general and administrative expense 70 64 61
Research and development expense 14 12 11
Equity and other income 0 0 0
Operating income (loss) [8] (12) (338) (32)
EBITDA [1] 51 (254) 89
Depreciation expense [9] 54 75 111
Intermediates [Member]      
Segment Reporting Information [Line Items]      
Goodwill impairment and loss on divestitures, net 0 0 0
Amortization expense 1 1 0
Additions to property, plant and equipment 4 3 2
Assets 116 116  
Property, plant and equipment, net 31 30  
Intermediates [Member] | Operating Segments [Member]      
Segment Reporting Information [Line Items]      
Sales 135 137 144
Cost of sales 117 121 107
Selling, general and administrative expense 6 7 7
Research and development expense 0 0 0
Equity and other income 0 0 0
Operating income (loss) 11 8 29
EBITDA [1] 16 21 42
Depreciation expense 4 12 13
Unallocated and Other [Member]      
Segment Reporting Information [Line Items]      
Selling, general and administrative expense 117 112 152
Research and development expense 4 2 3
Equity and other income 3 3 6
Goodwill impairment and loss on divestitures, net 8 161 115
Operating income (loss) [10] (126) (273) (264)
EBITDA [1] (125) (273) (264)
Depreciation expense [11] 1 0 0
Additions to property, plant and equipment 2 5 $ 2
Assets 1,324 1,226  
Property, plant and equipment, net $ 94 $ 105  
[1] Excludes loss from discontinued operations, net of income taxes and other net periodic benefit (income) loss. See the Statements of Consolidated Comprehensive Income (Loss) for applicable amounts excluded.
[2] Includes $5 million, $41 million and $57 million of accelerated depreciation during the years ended September 30, 2026, 2025 and 2024, respectively, related to plant optimization actions. See Note D for additional details.
[3] Intersegment sales from Intermediates are accounted for at prices that approximate market value. All other intersegment sales are accounted for at cost.
[4] Includes $16 million of capital projects impairment charges in 2026 and goodwill impairment of $375 million for Life Sciences in 2025.
[5] Depreciation includes accelerated depreciation of $21 million for Life Sciences in 2025.
[6] Includes capital projects impairment charge of $11 million for Personal Care in 2024.
[7] Depreciation includes accelerated depreciation of $1 million, $1 million and $2 million for Personal Care in 2026, 2025 and 2024, respectively.
[8] Includes $2 million of capital projects impairment charges in 2026 and goodwill impairment of $331 million for Specialty Additives in 2025.
[9] Depreciation includes accelerated depreciation of $3 million, $19 million and $55 million for Specialty Additives in 2026, 2025 and 2024, respectively.
[10] Includes a $3 million gain on sale of excess corporate properties, a $2 million excess land contract termination fee income and a $13 million Argentina foreign currency cumulative translation adjustment in 2026, $8 million gain on sale and a $183 million impairment charge related to the divestiture of the Avoca business in 2025, and a $8 million loss on sale and a $99 million impairment charge related to the divestiture of the Nutraceuticals business in 2024 within the loss on divestitures, net.
[11] Depreciation includes accelerated depreciation of $1 million for Unallocated and other in 2026.